Hypoalbuminaemia - A marker of cardiovascular disease in patients with chronic kidney disease stages II - IV

International Journal of Medical Sciences

Volumn 5, Issue 6, 2008, Pages 366-370

  Shah, Nehal Rachit ^a,c   Dumler, Francis ^b  

^a ST JOSEPH MERCY OAKLAND HOSPITAL   (United States)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

^c NONE   (United States)

Author keywords

Cardiovascular disease; Chronic kidney disease patients; Cross sectional study; Hypoalbuminaemia

Indexed keywords

SERUM ALBUMIN;

ADULT; AGE DISTRIBUTION; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE MARKER; DISEASE SEVERITY; DYSLIPIDEMIA; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATIENT IDENTIFICATION; PREDICTION; PROGNOSIS; RISK FACTOR; SEX DIFFERENCE;

EID: 56449117304     PISSN: None     EISSN: 14491907     Source Type: Journal    
DOI: 10.7150/ijms.5.366     Document Type: Article

References (51)

1. Renal Data System. USRDS 2003 annual data report: atlas of end-stage renal disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2003.
2. Locatelli F, Marcelli D, Conte F et al. Cardiovascular disease in chronic renal failure: the challenge continures. Registro Lombardo Dialisi e Trapianto. Nephrol Dial Transplant 2000; 15 (Suppl 5): 69-80.
3. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kideny Dis 1998; 32 (Suppl 3): S112-119.
4. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survery. Am J Kidney Dis 2003; 41: 1-12.
5. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community based cohort with mild renal insufficiency. Kidney Int. 1999; 56: 2214-19.
6. Shilpak MG, Fried LF, Crump C et al. Cardiovascular disease risk status in elderly persons with renal insufficiency. Kidney Int. 2003; 62: 997-1004.
7. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130: 461-470.
8. Levey AS, Greene T, Kusek JW, Beck GJ. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000; 11: 155A-155A.
9. Sarnak MJ, Levey AS, Schoolweth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-2169.
10. Shilpak MG, Simon JA, Grady D, Lin F, Wenger NK, Furberg CD. Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease. J Am Coll Cardiol 2001; 38: 705-
11. Shulman NB, Ford CE, Hall WD, et al. The Hypertension Detection and Follow-up Program Group. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function results from the Hypertension Detection and Follow-up Program. Hypertension. 1989 May;13(5 Suppl):I80-93.
12. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001; 134: 62
13. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
14. Kidney Disease Outcome Quality Initiative. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kideny Dis 2002; 39(suppl 2): S1-S24.
15. Linder A, Charea B, Sherrard DJ, et al. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 1974; :290-701.
16. Junger P, Massy ZA, Khoa TN, et al. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study. Nephrol Dial Transplant 1997; 12: 2597-2602.
17. Herzog CA, Ma JZ, Collins AJ. Poor long term survival after acute myocardial infarction among patients on long term dialysis. N Engl J Med 1998; 339: 799-805.
18. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephron. 1999; 10: 1606-1615.
19. D'Elia JA, Weinrauch LA, Gleason RE, et al. Application of the ambulatory 24-hour electrocardiogram in the prediction of cardiac death in dialysis patients. Arch Intern Med. 1988; 148: 2381-2385.
20. Aronow Ws. Usefulness of serum creatinine as a marker for coronary events in elderly patients with either systemic hypertension or diabetes mellitus. Am J Cardiol. 1991; 68: 678-679.
21. Levin A, Foley RN. Cardiovascular disease in chronic renal insufficiency. Am J Kidney Dis. 2003; 36: S24-30.
22. Danesh J, Collins R, Peto R. Lipoprotein (a) and coronary heart disease. Meta-analysis of prospective studies. Circulation. 2000; 102: 1082-5.
23. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis CE, et al. Lipoprotein (a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial. JAMA. 1994; 271: 999-1003.
24. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336: 973-9.
25. Bergstrom J, Lindholm B: Malnutrition, cardiac disease, and mortality: An integrated point of view. Am J Kidney Dis 1998; 32: 834-841.
26. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-658.
27. Foley RN, Parfrey PS, Harnett JD, et al. Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease. J Am Soc Nephrol 1996; 7: 728-736.
28. Owen WF, Lew NL, Liu Y, et al. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med. 1993; 329: 1001-1006.
29. Iseki K, Kawazoe N, Fukiyama K. Serum albumin is a strong predictor of death in chronic dialysis patients. Kidney Int 1993; 44: 115-119.
30. Avram MM, Mittman N, Bonomini L, et al. Markers for survival in dialysis: A seven-year prospective study. Am J Kidney Dis 1995; 26: 209-219.
31. Soriano S, González L, et al. C-reactive protein and low albumin are predictors of morbidity and cardiovascular events in chronic kidney disease (CKD) 3-5 patients. Clinical nephrology 2007; 67(6):352-7.
32. Beddhu S, Kaysen GA, Yan G, Sarnak M, Agodoa L, Ornt D, Cheung AK, HEMO Study Group. Association of serum albumin and atherosclerosis in chronic hemodialysis patients. Am J Kidney Dis 2002; 40: 721-727.
33. Owen WFJr, Lew NL, Liu Y, Lowrie EG, Lazarus JM. The reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993; 329: 1001-1006.
34. Kalantar-Zadeh K, Kilpatrick RD, Kuwae N et al. Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction. Nephrol Dial Transplant 2005; 20: 1880-1888.
35. Kaysen GA, Dubin JA, Muller HG, Rosales L, Levin NW, Mitch WE, HEMO study group. Inflammation and reduced albumin systhesis associated with stable decline in serum albumin in hemodialysis patients. Kidney Int 2004; 65: 1408-1415.
36. Nacimiento MM, Pecoits-Filho R, Qureshi AR et al. The prognostic impact of fluctuating levels of C-reactive protein in Brazilian haemodialysis patients: a prospective study. Nephrol Dial Transplant 2004; 19: 2803-2809.
37. Tsirpanlis G, Bagos P, Ioannou D et al. Exploring inflammation in hemodialysis patients: persistent and superimposed inflammation. A longitudinal study. Kidney Blood Press Res 2004; 27: 63-70.
38. Stevinkel P, Heimburger O, Paultre F et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899-1911.
39. Nobuhiko Joki, Hiroki Hase, Yuri Tanaka et al. Relationship between serum albumin level before initiating haemodialysis and angiographic severity of coronary atherosclerosis in end-stage renal disease. Nephrol Dial Transplant 2006; 21(6): 1633-1639.
40. Kalantar-Zadeh K, Kopple JD, Block G, et al. A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. Am J Kidney Dis 2001; 38: 1251-1263.
41. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840-844.
42. Mitch WE. Malnutrition: a frequent misdiagnosis for hemodialysis patients. J Clin Invest 2002; 110: 437-439.
43. Kaysen GA. Biological basis of hypoalbuminemia in ESRD. J Am Soc Nephrol 1998; 9: 2368-2376.
44. Kaysen GA, Dubin JA, Muller HG, Rosales LM, Levin NW. The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients. The HEMO Study Group. Kidney Int 2000; 58: 346-352.
45. Kaysen GA, Chertow GM, Adhikarla R, Young B, Ronco C, Levin NW. Inflammation and dietary protein intake exert competing effects on serum albumin and creatinine in hemodialysis patients. Kidney Int 2001; 60: 333-340.
46. Himmelfarb J, Stenvinkel P, Ikizler TA, and Hakim RM: The elephant of uremia: oxidative stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524-1538.
47. Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy. Sem Dial 2002; 15: 329-337.
48. Wanner C, Metzger T. C-reactive protein - a marker for all-cause and cardiovascular mortality in haemodialysis patients. Nephrol Dial Transplant 2002; 17(Supply 8): 29-32.
49. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003; 361(9364): 1149-58.
50. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360(9326): 7-22.
51. Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004; 110(12): 1557-63.